NEW YORK, April 1, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver and intestinal diseases, today announced that it has commenced an underwritten public offering of 1,000,000 shares of its common stock. 600,000 of the shares in the offering are to be sold by Intercept and 400,000 are to be sold by certain institutional selling stockholders.
Help employers find you! Check out all the jobs and post your resume.
